ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "treatment"

  • Abstract Number: 557 • ACR/ARP Annual Meeting 2019

    Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

    Theresa Hunter1, David Sandoval 2, Nicola Booth 3, Elizabeth Holdsworth 4 and Atul Deodhar 5, 1Eli Lilly and Company, Indianapolis, 2Eli Lilly and Company, Indianapolis, IN, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Manchester, England, United Kingdom, 5Oregon Health & Science University, Portland, OR

    Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
  • Abstract Number: 1400 • ACR/ARP Annual Meeting 2019

    Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis

    Aniela Croiteru 1, Merav Lidar 2, Tatiana Reitblat3, Devy Zisman 4, Alexandra Balbir-Gurman 5, Tanya Meshiach 5, Ronit Almog 5 and Ori Elkayam 6, 1Tel Aviv medical center, Tel Aviv, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Barzilai Medical Center, Ashkelon, Israel, 4Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, 5Rambam Medical Center, Haifa, Israel, 6Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel

    Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited.  We sought to analyze…
  • Abstract Number: 2162 • ACR/ARP Annual Meeting 2019

    Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)

    Shuji Asai1, Toshihisa Kojima 1, Nobunori Takahashi 1 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
  • Abstract Number: 504 • ACR/ARP Annual Meeting 2019

    A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

    Kenneth Kalunian1, Mark Genovese 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, Alena Pechonkina 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, Kurt de Vlam 6, David Walker 7 and Tsutomu Takeuchi 8, 1Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 2Stanford University, Stanford, CA, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 7Northumbria Healthcare, Northumbria, United Kingdom, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…
  • Abstract Number: 614 • ACR/ARP Annual Meeting 2019

    Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data

    Bon San Koo1, Yu-Cheol Lim 2, Min-Young Lee 3, Ja-Young Jeon 4, Hyun-Jeong Yoo 5, In-Sun Oh 2, Ju-Young Shin 2 and Tae-Hwan Kim 6, 1Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 2School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea, 3VIAplus, Siheung, Republic of Korea, 4Pfizer Inc, Seoul, Republic of Korea, 5Pfizer Korea, Seoul, Republic of Korea, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…
  • Abstract Number: 1404 • ACR/ARP Annual Meeting 2019

    Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea

    Min Jung Kim1, Anna Shin 2, Seonghwan Shin 2, You-Jung Ha 3, Yun Jong Lee 4, Eun Bong Lee 5, Yeong-Wook Song 1 and Eun Ha Kang 3, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul

    Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
  • Abstract Number: 2361 • ACR/ARP Annual Meeting 2019

    Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

    Mariangelí Arroyo-Ávila1, Ruth Fred-Jiménez 1, Naydi Pérez-Ríos 1, Noelia Rodríguez 1, Grissel Ríos 1 and Luis Vilá 1, 1University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
  • Abstract Number: 507 • ACR/ARP Annual Meeting 2019

    Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Mitsuhiro Rokuda 3, Hiroyuki Izutsu 3, Yuichiro Kaneko 3, Musashi Fukuda 3, Daisuke Kato 3 and Désirée van der Heijde 4, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Astellas Pharma, Inc., Tokyo, Japan, 4Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
  • Abstract Number: 757 • ACR/ARP Annual Meeting 2019

    Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

    Hajime Yoshifuji1, Haruhito Uchida 2, Yoshikazu Nakaoka 3, Takahiko Sugihara 4, Mitsuaki Isobe 5 and Masayoshi Harigai 6, 1Kyoto University, Kyoto, Japan, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Sakakibara Heart Institute, Tokyo, Japan, 6Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
  • Abstract Number: 1406 • ACR/ARP Annual Meeting 2019

    Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

    Maxime Verhoeven1, Janneke Tekstra 1, Attila Pethö-Schramm 2, Michelle Borm 3, Jacob van Laar 1, Floris Lafeber 1, Johannes Bijlsma 1, Johannes Jacobs 1 and Paco Welsing 1, 1UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 2Hoffmann-La Roche, Basel, Basel, Switzerland, 3Roche Nederland BV, Woerden, Netherlands

    Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
  • Abstract Number: 2373 • ACR/ARP Annual Meeting 2019

    Two Decades of Changes in RA Treatment and Disease Outcomes from the United States

    Sofia Pedro1, Alyssa Dominique 2, Rebecca Schumacher 1, Yomei Shaw 1, Kristin Wipfler 1, Teresa Simon 3 and Kaleb Michaud 4, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Bristol-Myers Squibb, Princeton, NJ, 3Bristol-Myers Squibb*, Princeton, NJ, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…
  • Abstract Number: 508 • ACR/ARP Annual Meeting 2019

    Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Sakae Tanaka 3, Atsushi Kawakami 4, Yeong-Wook Song 5, Yi-Hsing Chen 6, Mitsuhiro Rokuda 7, Hiroyuki Izutsu 7, Satoshi Ushijima 7, Yuichiro Kaneko 7, Yoshihiro Nakashima 7, Teruaki Shiomi 7 and Emi Yamada 7, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3University of Tokyo, Tokyo, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Seoul National University Hospital, Seoul, Republic of Korea, 6Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 7Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
  • Abstract Number: 766 • ACR/ARP Annual Meeting 2019

    Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica

    Akiko Aoki1, Hiroshi Kobayashi 1 and Hiroshi Oka 1, 1Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan

    Background/Purpose: Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GC), but relapses and long-term GC therapy are common. 2015 EULAR/ACR recommendations suggest…
  • Abstract Number: 1422 • ACR/ARP Annual Meeting 2019

    Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Sean Connolly 7, Kuan-Hsiang Gary Huang 7, Yedid Elbez 8, Sumanta Mukherjee 7 and Roy Fleischmann 9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
  • Abstract Number: 2377 • ACR/ARP Annual Meeting 2019

    Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 22
  • Next Page

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology